These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37872650)

  • 1. MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia.
    Shovlin CL; Patel D; Bielowka A; Ledermann JA; Modarresi A; ; Bernabeu-Herrero ME; Aldred MA; Alsafi A
    Br J Haematol; 2024 Jan; 204(1):361-365. PubMed ID: 37872650
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
    Harrison L; Kundra A; Jervis P
    J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series.
    Joshi H; Woodworth BA; Carney AS
    J Laryngol Otol; 2011 Nov; 125(11):1176-80. PubMed ID: 21846415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based management of epistaxis in hereditary haemorrhagic telangiectasia.
    Syed I; Sunkaraneni VS
    J Laryngol Otol; 2015 May; 129(5):410-5. PubMed ID: 25736077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A natural obturator in hereditary haemorrhagic telangiectasia.
    Soni-Jaiswal A; Woolford TJ
    J Laryngol Otol; 2009 Jun; 123(6):695-6. PubMed ID: 19275781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.
    Invernizzi R; Quaglia F; Klersy C; Pagella F; Ornati F; Chu F; Matti E; Spinozzi G; Plumitallo S; Grignani P; Olivieri C; Bastia R; Bellistri F; Danesino C; Benazzo M; Balduini CL
    Lancet Haematol; 2015 Nov; 2(11):e465-73. PubMed ID: 26686256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia.
    Lennox PA; Harries M; Lund VJ; Howard DJ
    J Laryngol Otol; 1997 Jan; 111(1):34-7. PubMed ID: 9292128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endovascular treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.
    Layton KF; Kallmes DF; Gray LA; Cloft HJ
    AJNR Am J Neuroradiol; 2007 May; 28(5):885-8. PubMed ID: 17494663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
    Ghosh K; Ghosh K
    Thromb Haemost; 2008 Jul; 100(1):162-4. PubMed ID: 18612556
    [No Abstract]   [Full Text] [Related]  

  • 11. Ischaemic stroke in a 21-year-old with hereditary haemorrhagic telangiectasia.
    Kane I; Pitt Ford A; Lawton K; Poitelea M; Gainsborough N
    Pract Neurol; 2016 Oct; 16(5):381-4. PubMed ID: 27334289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domiciliary floseal prevents admission for epistaxis in hereditary hemorrhagic telangiectasia.
    Warner L; Halliday J; James K; de Carpentier J
    Laryngoscope; 2014 Oct; 124(10):2238-40. PubMed ID: 24706356
    [No Abstract]   [Full Text] [Related]  

  • 13. Hereditary hemorrhagic telangiectasia: a rare cause of severe anemia.
    dos Santos JW; Dalcin TC; Neves KR; Mann KC; Pretto GL; Bertolazi AN
    J Bras Pneumol; 2007; 33(1):109-12. PubMed ID: 17568877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary haemorrhagic telangiectasia: Young's procedure in the management of epistaxis.
    Hosni AA; Innes AJ
    J Laryngol Otol; 1994 Sep; 108(9):754-7. PubMed ID: 7964136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency for Treatment of Refractory Epistaxis in Hereditary Hemorrhagic Telangiectasia.
    Donato M; Pimentel J; Cabral R; Escada P
    Acta Med Port; 2018 Jan; 31(1):63-66. PubMed ID: 29573771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary haemorrhagic telangiectasia.
    Rimmer J; Lund VJ
    Rhinology; 2015 Sep; 53(3):195-203. PubMed ID: 26460394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epistaxis in people with hereditary haemorrhagic telangiectasia: surgical management and psychological impact.
    Crouch-Smith HA; Fenn KJ; Williams SP
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-10. PubMed ID: 34817260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epistaxis in hereditary haemorrhagic telangiectasia.
    Haitjema T; Balder W; Disch FJ; Westermann CJ
    Rhinology; 1996 Sep; 34(3):176-8. PubMed ID: 8938889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.